Breast Cancer Clinical Trial
Green Tea and Reduction of Breast Cancer Risk
Summary
RATIONALE: Green tea extract contains ingredients (catechins) that may lower the risk of breast cancer.
PURPOSE: This phase II trial is studying how well green tea extract works in preventing breast cancer compared to a placebo in postmenopausal women with high breast density.
The investigators have hypothesized that green tea consumption reduces breast cancer risk, and this effect is seen primarily in women who have the low-activity COMT genotype. The investigators will test this by evaluating the effects of green tea extract on breast cancer biomarkers including mammographic density, plasma insulin-like growth factor 1 (IGF-1), IGF binding protein 3 (IGFBP-3), estrone, estradiol, androstenedione, sex hormone binding globulin (SHBG), urinary estrogen metabolites and plasma F2-isoprostanes.
Full Description
OBJECTIVES:
Primary:
1.1 To determine the effects of green tea extract consumption (containing 800 mg EGCG per day) for 12 months on the following recognized biomarkers of breast cancer risk:
Mammographic density
Circulating concentrations of insulin-like growth factor 1 (IGF-1) and IGF binding protein 3 (IGFBP-3)
Circulating concentrations of reproductive hormones (estrone, estradiol, androstenedione) and sex hormone binding globulin (SHBG)
1.2 To determine the effects of COMT genotype on the green tea extract effects described above.
Secondary:
2.1 To determine the effects of green tea extract consumption (containing 800 mg EGCG per day) for 12 months on the following hypothesized biomarkers of breast cancer risk:
Urinary estrogen metabolites (estrone, estradiol, and their 2-hydroxy, 4-hydroxy, 2-methoxy, and 4-methoxy metabolites, estriol, and 16- hydroxyestrone)
Circulating concentrations of F-2 isoprostanes, a recognized biomarker of systemic oxidative stress
2.2 To determine the effects of COMT genotype on the green tea extract effects described above.
2.3 To determine the effects of COMT genotype on catechin metabolism and excretion, as measured by circulating and urinary concentrations.
Eligibility Criteria
Inclusion Criteria:
Signed informed consent
Healthy postmenopausal women aged 50-70 years
"Heterogeneously dense" (51-75% glandular) or "extremely dense" (>75%glandular) breasts
Willing to avoid consumption of green tea for 1 year
Exclusion Criteria:
Positive serological markers of hepatitis B or hepatitis C infections
Elevated levels of liver enzymes
Recent (within 6 mo) or current hormone or hormone modification therapy, including systemic hormone replacement therapy, SERMS and aromatase inhibitors
Current smoker of cigarettes or other tobacco products
BMI <19 or >40 kg/m2
Weight change > 10 lbs during the previous year
History of breast cancer or proliferative breast disease
Regular consumption of > 7 alcoholic drinks/wk
Regular consumption of green tea (>1 cup/wk)
Recent (within 6 mo) or current use of chemopreventive agents such as tamoxifen, raloxifene or aromatase inhibitors
Participation in any weight loss or weight gain studies
Currently taking Methotrexate or Enbrel
History of ovarian cancer
Any form of cancer in the last 5 years
Presence of implants
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Edina Minnesota, 55435, United States
Maple Grove Minnesota, 55369, United States
Minneapolis Minnesota, 55455, United States
St. Louis Park Minnesota, 55426, United States
St. Paul Minnesota, 55108, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.